A Phase 3 interventional study of abatacept and placebo in Crohn's Disease, sponsored by Bristol-Myers Squibb. Terminated at 101 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-09-14.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Crohn Disease by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Crohn Disease · Bristol-Myers Squibb.
Among the 16 studies in Crohn Disease by Bristol-Myers Squibb, this one is the 6th largest by enrollment, is the only one that started in 2006, is one of 8 in phase 3, and was the 1st registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →None of the 16 studies in Crohn Disease by Bristol-Myers Squibb is open now. The open studies under Crohn Disease, anywhere →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 9
First in 2002; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 451 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 180 across the 16 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Crohn Disease by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn's Disease in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied.
Inclusion Criteria:
4 arms for induction period 2 arms for maintenance period
Drug: abatacept
4 arms for induction period 2 arms for maintenance period
Drug: placebo
1 arm for open-label extension phase
Drug: abatacept
Dextrose 5% in water, intravenous (IV). Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; \~10 mg/kg on days IP-1, IP-15,IP-29, IP-57, or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57. Induction Period 3 months Maintenance Period 12 months
Also known as: Orencia, BMS-188667
Normal saline, IV, 0 mg/kg, every 28 days. Induction Period 3 months Maintenance Period 12 months
\~10 mg/kg, every 28 days. Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued
Also known as: Orencia, BMS-188667
Induction Period (IP); Number of Participants With Crohn's Disease Activity Index (CDAI)-Defined Clinical Response at Both Day IP-57 and Day IP-85
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12).
Maintenance Period (MP); Number of Participants In CDAI-Defined Clinical Remission (CDAI <150) at Day MP-365 (12 Months)
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: Day MP-365 (12 months) of maintenance therapy
Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due to AEs
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Time frame: Between Day OL-1 and Day OL-617
OL; Number of Participants With Adverse Events (AEs) of Special Interest
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
Time frame: Between Day OL-1 and Day OL-617
IP; Number of Participants in CDAI-defined Clinical Remission at Both Day IP-57 and Day IP-85 (Key Secondary Outcome)
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
IP; Change From Baseline to Day IP-85 In Inflammatory Bowel Disease Questionnaire (IBDQ)
The Inflammatory Bowel Disease Questionnaire (IBDQ) consists of a self-administered 32-item questionnaire evaluating quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. Responses to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score ranges between 32 to 224 with higher scores indicating a better quality of life. Change from Baseline= post-Baseline - Baseline value.
Time frame: Baseline, Day IP-85
IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due to AEs
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Time frame: Day IP-1 through Day IP-85
IP; Number of Participants With Adverse Events (AEs) of Special Interest
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
Time frame: Day IP-1 through Day IP-85
IP; Number of Participants With Positive Antibody Response to Abatacept (ABA)
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition identified specific anti-ABA reactivity. Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Possibly immunoglobulin (Ig) category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
Time frame: For participants treated in MP: Day IP-1 (Baseline) to Day MP-1 (Day IP-85); For participants treated in OL directly after IP: Day IP-1 to Day OL-1; For participants treated only in IP: All measurements after Day IP-1 (including follow-up visits)
IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF)
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
IP; Number of Participants in CDAI-Defined Clinical Remission at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-TNF
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: At both Day IP-57 (Wk 8) and Day IP-85 (Wk 12) of induction therapy
MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and Discontinuation Due To AEs
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Time frame: Between Day IP-85 and Day MP-365
MP; Number of Participants With Adverse Events (AEs) of Special Interest:
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
Time frame: Between Day IP-85 and Day MP-365
MP; Number of Participants With Positive Antibody Response to Abatacept
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
Time frame: For participants not entering OL: All measurements after Day MP-1 (including follow-up visits); For participants entering OL: From first measurement after Day MP-1 to Day MP-365 (Day OL-1)
MP; Number of Participants With CDAI-defined Clinical Response at Day MP-365.
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: Day MP-365
MP; Number of Participants in CDAI-defined Clinical Remission at Both Day MP-169 and Day MP-365
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: Day MP-169
MP; Change From Baseline to Day MP-365 in Short Form-36 (SF-36)
The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.
Time frame: Baseline, Day MP-365
MP; Change From Baseline to Day MP-365 in Inflammatory Bowel Disease Questionnaire (IBDQ)
The Inflammatory Bowel Disease Questionnaire (IBDQ) consists of a self-administered 32-item questionnaire evaluating quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. Responses to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score ranges between 32 to 224 with higher scores indicating a better quality of life. Change from Baseline= post-baseline - Baseline value.
Time frame: Baseline, Day MP-365
MP; Number of Participants Who Were Not On Background Corticosteroid Therapy at Day MP-365 Among All Participants Who Received Baseline Corticosteroid Therapy
Participants who received corticosteroid therapy (e.g. prednisone or budesonide) were to maintain a stable dose until Day MP-1. On or after Day MP-1, a recommended tapering regimen of corticosteroid therapy was planned if the participant was in remission (i.e., CDAI score \< 150), or if the participant's condition had satisfactorily improved according to investigators clinical assessment. Other CD therapy was to remain at a stable dose throughout the Maintenance Period, with the exception of decreases due to drug-related toxicities.
Time frame: Day MP-365
MP; Number of Participants Who Were Not On Background Corticosteroid Therapy at Day MP-365 Among Participants Who Received Baseline Corticosteroid Therapy and Who Achieved CDAI-Defined Clinical Remission
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score is based partly on entries from participant's Diary (7 days before evaluation) which is kept while on study. CDAI scores range from 0 to \~600. Clinical response=CDAI reduction ≥100 or absolute CDAI \<150. Clinical remission=CDAI \<150. Moderate to severe disease=CDAI ≥220 and ≤450.
Time frame: Day MP-365
MP; Number of Participants With CDAI-Defined Clinical Response Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF)
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: Day MP-365
MP; Number of Participants in CDAI-Defined Clinical Remission Among Participants With Inadequate Response and/or Intolerance to Anti-TNF
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: Day MP-365
OL; Number of Participants Who Were Not On Background Corticosteroid Therapy Among All Participants Who Received Baseline Corticosteroid Therapy
Background corticosteroid therapy included prednisone or budesonide.
Time frame: Between Day OL-1 and Day OL-617
OL; Number of Participants With CDAI-defined Clinical Response or Clinical Remission at Day OL-169
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: Day OL-169
OL; Number of Participants With CDAI-defined Clinical Response or Clinical Remission at Day OL-365
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
Time frame: Day OL-365
OL; Number of Participants With Positive Antibody Response to Abatacept
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
Time frame: For participants receiving OL medication, all measurements starting after Day OL-1 (including follow-up visits and at 56 and 85 days after last dose)
OL; Number of Participants With Pharmacogenomic Marker Activity
Changes in the expression of individual ribonucleic acid (RNA) transcripts were to be evaluated from whole blood using both microarray transcriptional profiling and quantitative polymerase chain reaction (PCR) methods. Peripheral RNA transcriptional profiling was to be used only to identify individual RNA transcripts that differ in expression with respect to time, treatment and outcome.
Time frame: Between Day OL-1 and Day OL-617
| Milestone | Abatacept (ABA) 30/~10 mg/kg, Induction Period (IP) | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP | ABA ~10 mg/kg, Maintenance Period (MP) | Placebo, MP | ABA ~10 mg/kg, Open-Label Period (OL) |
|---|---|---|---|---|---|---|---|
| Started | 65 | 128 | 130 | 128 | 0 | 0 | 0 |
| Completed | 50 | 94 | 112 | 102 | 0 | 0 | 0 |
| Not completed | 15 | 34 | 18 | 26 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 10 | 4 | 11 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 11 | 14 | 8 | 10 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent | 2 | 5 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Subject no longer meets study criteria | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Declined participation but followup done | 0 | 2 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Given prohibited drug | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Incarcerated | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Patient relocated | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Abatacept (ABA) 30/~10 mg/kg, Induction Period (IP) | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP | ABA ~10 mg/kg, Maintenance Period (MP) | Placebo, MP | ABA ~10 mg/kg, Open-Label Period (OL) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 44 | 46 | 0 |
| Completed | 0 | 0 | 0 | 0 | 14 | 10 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 30 | 36 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 20 | 26 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Withdrawal of consent | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Administrative reason by sponsor | 0 | 0 | 0 | 0 | 4 | 7 | 0 |
| Withdrew: Error in disease score evaluation | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Abatacept (ABA) 30/~10 mg/kg, Induction Period (IP) | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP | ABA ~10 mg/kg, Maintenance Period (MP) | Placebo, MP | ABA ~10 mg/kg, Open-Label Period (OL) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 324 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 324 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 18 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 160 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Withdrawal of consent | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| Withdrew: Subject no longer meets study criteria | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Administrative reason by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 115 |
| Withdrew: Declined participation but followup done | 0 | 0 | 0 | 0 | 0 | 0 | 8 |
| Withdrew: Discontinued by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Refused followup | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
| participants | ABA 30/~10 mg/kg, IP | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP |
|---|---|---|---|---|
| Induction Period (IP); Number of Participants With Crohn's Disease Activity Index (CDAI)-Defined Clinical Response at Both Day IP-57 and Day IP-85 | 11 | 13 | 20 | 18 |
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
| participants | ABA ~10 mg/kg, MP | Placebo, MP |
|---|---|---|
| Maintenance Period (MP); Number of Participants In CDAI-Defined Clinical Remission (CDAI <150) at Day MP-365 (12 Months) | 10 | 5 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
| participants | ABA ~10 mg/kg, OL |
|---|---|
| AEs | 267 |
| Related AEs | 128 |
| Deaths | 1 |
| SAEs | 86 |
| Related SAEs | 21 |
| Discontinuation due to AE | 16 |
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
| participants | ABA 30/~10 mg/kg, IP | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP |
|---|---|---|---|---|
| IP; Number of Participants in CDAI-defined Clinical Remission at Both Day IP-57 and Day IP-85 (Key Secondary Outcome) | 5 | 5 | 6 | 8 |
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
| participants | Placebo, IP | ABA 3 mg/kg, IP | ABA ~10 mg/kg, IP | ABA 30/~10 mg/kg, IP |
|---|---|---|---|---|
| IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship | 18 | 20 | 13 | 11 |
The Inflammatory Bowel Disease Questionnaire (IBDQ) consists of a self-administered 32-item questionnaire evaluating quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. Responses to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score ranges between 32 to 224 with higher scores indicating a better quality of life. Change from Baseline= post-Baseline - Baseline value.
| units on a scale | ABA 30/~10 mg/kg, IP | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP |
|---|---|---|---|---|
| IP; Change From Baseline to Day IP-85 In Inflammatory Bowel Disease Questionnaire (IBDQ) | 0.79 ± 3.974 | 11.10 ± 2.858 | 7.53 ± 2.765 | 13.4 ± 2.798 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
| Participants | ABA 30/~10 mg/kg, IP | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP |
|---|---|---|---|---|
| AEs | 49 | 97 | 96 | 95 |
| Related AEs | 24 | 47 | 46 | 40 |
| Deaths | 0 | 0 | 0 | 0 |
| SAEs | 11 | 22 | 20 | 20 |
| Related SAEs | 2 | 7 | 9 | 6 |
| Discontinuation due to AE | 1 | 11 | 5 | 12 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
| participants | ABA 30/~10 mg/kg, IP | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP |
|---|---|---|---|---|
| All Infections | 13 | 33 | 31 | 42 |
| Serious Infections | 2 | 9 | 4 | 3 |
| Opportunistic Infections | 0 | 0 | 0 | 0 |
| Malignancies-Total | 0 | 0 | 3 | 0 |
| Malignancies-squamous cell carcinoma | 0 | 0 | 2 | 0 |
| Malignancies-breast cancer | 0 | 0 | 1 | 0 |
| Autoimmune Disorders-Total | 2 | 1 | 2 | 2 |
| Autoimmune Disorders-erythema | 2 | 1 | 2 | 1 |
| Autoimmune Disorders-psoriasis | 0 | 0 | 0 | 1 |
| Acute Infusional AEs | 3 | 3 | 4 | 5 |
| Peri-infusional AEs | 13 | 22 | 15 | 16 |
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition identified specific anti-ABA reactivity. Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Possibly immunoglobulin (Ig) category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
| participants | ABA 30/~10 mg/kg, IP | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP |
|---|---|---|---|
| Total | 4 | 7 | 12 |
| CTLA4/Possibly Ig | 1 | 0 | 6 |
| Ig and/or Ig Junction | 3 | 7 | 6 |
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
| participants | ABA 30/~10 mg/kg, IP | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP |
|---|---|---|---|---|
| IP; Number of Participants With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-Tumor Necrosis Factor (TNF) | 9 | 8 | 2 | 10 |
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
| participants | ABA 30/~10 mg/kg, IP | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP |
|---|---|---|---|---|
| IP; Number of Participants in CDAI-Defined Clinical Remission at Both Day IP-57 and Day IP-85 Among Participants With Inadequate Response and/or Intolerance to Anti-TNF | 3 | 2 | 0 | 3 |
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
| participants | Placebo, IP | ABA 3 mg/kg, IP | ABA ~10 mg/kg, IP | ABA 30/~10 mg/kg, IP |
|---|---|---|---|---|
| IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With CDAI-Defined Clinical Response at Both Day IP-57 and Day IP-85 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship | 10 | 2 | 8 | 9 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
| Participants | ABA ~10 mg/kg, MP | Placebo, MP |
|---|---|---|
| AEs | 31 | 32 |
| Related AEs | 12 | 15 |
| Deaths | 0 | 0 |
| SAEs | 5 | 9 |
| Related SAEs | 0 | 1 |
| Discontinuation due to AE | 1 | 0 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
| participants | ABA ~10 mg/kg, MP | Placebo, MP |
|---|---|---|
| All Infections | 16 | 18 |
| Serious Infections | 1 | 1 |
| Opportunistic Infections | 0 | 0 |
| Malignancies | 0 | 0 |
| Autoimmune Disorders-Total | 2 | 1 |
| Autoimmune Disorders-psoriasis | 2 | 0 |
| Autoimmune Disorders-erythema | 0 | 1 |
| Acute Infusional AEs | 1 | 0 |
| Peri-infusional AEs | 2 | 0 |
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
| participants | ABA ~10 mg/kg, MP | Placebo, MP |
|---|---|---|
| Total | 7 | 14 |
| CTLA4/Possibly Ig | 2 | 8 |
| Ig and/or Ig Junction | 5 | 8 |
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
| participants | ABA ~10 mg/kg, MP | Placebo, MP |
|---|---|---|
| MP; Number of Participants With CDAI-defined Clinical Response at Day MP-365. | 11 | 7 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
| participants | ABA ~10 mg/kg, OL |
|---|---|
| All Infections | 144 |
| Serious Infections | 13 |
| Opportunistic Infections (OI)-Total | 2 |
| OI-oral candidiasis | 1 |
| OI-gastroenteritis Cryptosporidial | 1 |
| Malignancies-Total | 5 |
| Malignancies-basal cell carcinoma | 2 |
| Malignancies-breast cancer | 1 |
| Malignancies-squamous cell carcinoma | 1 |
| Malignancies-chronic lymphocytic leukemia | 1 |
| Autoimmune Disorders-Total | 11 |
| Autoimmune Disorders-erythema nodosum | 7 |
| Autoimmune Disorders-psoriasis | 1 |
| Autoimmune Disorders-pernicious anemia | 1 |
| Autoimmune Disorders-antiphospholipid syndrome | 1 |
| Autoimmune Disorders-ankylosing spondylitis | 1 |
| Acute Infusional AEs | 10 |
| Peri-infusional AEs | 24 |
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
No measurements were reported for this outcome.
The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.
No measurements were reported for this outcome.
The Inflammatory Bowel Disease Questionnaire (IBDQ) consists of a self-administered 32-item questionnaire evaluating quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. Responses to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score ranges between 32 to 224 with higher scores indicating a better quality of life. Change from Baseline= post-baseline - Baseline value.
No measurements were reported for this outcome.
Participants who received corticosteroid therapy (e.g. prednisone or budesonide) were to maintain a stable dose until Day MP-1. On or after Day MP-1, a recommended tapering regimen of corticosteroid therapy was planned if the participant was in remission (i.e., CDAI score \< 150), or if the participant's condition had satisfactorily improved according to investigators clinical assessment. Other CD therapy was to remain at a stable dose throughout the Maintenance Period, with the exception of decreases due to drug-related toxicities.
No measurements were reported for this outcome.
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score is based partly on entries from participant's Diary (7 days before evaluation) which is kept while on study. CDAI scores range from 0 to \~600. Clinical response=CDAI reduction ≥100 or absolute CDAI \<150. Clinical remission=CDAI \<150. Moderate to severe disease=CDAI ≥220 and ≤450.
No measurements were reported for this outcome.
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
No measurements were reported for this outcome.
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
No measurements were reported for this outcome.
Background corticosteroid therapy included prednisone or budesonide.
No measurements were reported for this outcome.
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
| participants | ABA ~10 mg/kg, OL |
|---|---|
| Clinical Response | 84 |
| Clinical Remission | 55 |
CDAI is a composite index consisting of a weighted scoring of 8 disease variables:number of liquid stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's Diary kept while on study. CDAI scores range from 0 to \~600 points. Clinical response=CDAI reduction ≥100 points or absolute CDAI \<150 points. Clinical remission=CDAI \<150 points. Moderate to severe disease=CDAI ≥220 and ≤450 points.
| participants | ABA ~10 mg/kg, OL |
|---|---|
| Clinical Response | 35 |
| Clinical Remission | 24 |
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category= reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
| participants | ABA ~10 mg/kg, OL |
|---|---|
| Total | 71 |
| CTLA4/Possibly Ig | 46 |
| Ig and/or Ig Junction | 29 |
Changes in the expression of individual ribonucleic acid (RNA) transcripts were to be evaluated from whole blood using both microarray transcriptional profiling and quantitative polymerase chain reaction (PCR) methods. Peripheral RNA transcriptional profiling was to be used only to identify individual RNA transcripts that differ in expression with respect to time, treatment and outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABA 30/~10mg/kg (IP) | — | 11/65 (16.9%) | 34/65 (52.3%) |
| ABA 3mg/kg (IP) | — | 20/130 (15.4%) | 48/130 (36.9%) |
| ABA ~10mg/kg (IP) | — | 22/128 (17.2%) | 45/128 (35.2%) |
| ABA ~10mg/kg (MP) | — | 5/44 (11.4%) | 19/44 (43.2%) |
| ABA ~10mg/kg (OL) | — | 86/324 (26.5%) | 150/324 (46.3%) |
| Placebo (IP) | — | 20/128 (15.6%) | 60/128 (46.9%) |
| Placebo (MP) | — | 9/46 (19.6%) | 17/46 (37%) |
| Event | ABA 30/~10mg/kg (IP) | ABA 3mg/kg (IP) | ABA ~10mg/kg (IP) | ABA ~10mg/kg (MP) | ABA ~10mg/kg (OL) | Placebo (IP) | Placebo (MP) |
|---|---|---|---|---|---|---|---|
| CROHN'S DISEASEGastrointestinal disorders | 5/65 | 9/130 | 9/128 | 2/44 | 35/324 | 10/128 | 3/46 |
| ANAL ABSCESSInfections and infestations | 0/65 | 3/130 | 4/128 | 0/44 | 3/324 | 1/128 | 0/46 |
| ABDOMINAL PAINGastrointestinal disorders | 0/65 | 2/130 | 0/128 | 1/44 | 3/324 | 0/128 | 0/46 |
| BRONCHITISInfections and infestations | 1/65 | 0/130 | 0/128 | 1/44 | 0/324 | 0/128 | 0/46 |
| CALCULUS URETERICRenal and urinary disorders | 0/65 | 0/130 | 1/128 | 1/44 | 0/324 | 0/128 | 0/46 |
| ROAD TRAFFIC ACCIDENTInjury, poisoning and procedural complications | 0/65 | 0/130 | 0/128 | 1/44 | 0/324 | 0/128 | 0/46 |
| ANAL FISTULAGastrointestinal disorders | 0/65 | 0/130 | 0/128 | 0/44 | 1/324 | 0/128 | 1/46 |
| GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 0/65 | 0/130 | 0/128 | 0/44 | 0/324 | 0/128 | 1/46 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 1/65 | 0/130 | 1/128 | 0/44 | 3/324 | 0/128 | 1/46 |
| CLOSTRIDIUM DIFFICILE COLITISInfections and infestations | 1/65 | 0/130 | 0/128 | 0/44 | 3/324 | 0/128 | 1/46 |
| Event | ABA 30/~10mg/kg (IP) | ABA 3mg/kg (IP) | ABA ~10mg/kg (IP) | ABA ~10mg/kg (MP) | ABA ~10mg/kg (OL) | Placebo (IP) | Placebo (MP) |
|---|---|---|---|---|---|---|---|
| PYREXIAGeneral disorders | 9/65 | 4/130 | 5/128 | 0/44 | 21/324 | 10/128 | 4/46 |
| NAUSEAGastrointestinal disorders | 6/65 | 11/130 | 9/128 | 5/44 | 35/324 | 9/128 | 2/46 |
| HEADACHENervous system disorders | 7/65 | 12/130 | 13/128 | 2/44 | 30/324 | 8/128 | 3/46 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 7/65 | 9/130 | 7/128 | 3/44 | 27/324 | 8/128 | 3/46 |
| VOMITINGGastrointestinal disorders | 5/65 | 3/130 | 2/128 | 3/44 | 23/324 | 8/128 | 4/46 |
| NASOPHARYNGITISInfections and infestations | 1/65 | 7/130 | 2/128 | 1/44 | 25/324 | 5/128 | 4/46 |
| ABDOMINAL PAINGastrointestinal disorders | 4/65 | 3/130 | 7/128 | 3/44 | 26/324 | 7/128 | 3/46 |
| FATIGUEGeneral disorders | 5/65 | 8/130 | 4/128 | 3/44 | 22/324 | 10/128 | 0/46 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/65 | 5/130 | 0/128 | 3/44 | 25/324 | 6/128 | 3/46 |
| MOUTH ULCERATIONGastrointestinal disorders | 1/65 | 1/130 | 1/128 | 3/44 | 3/324 | 0/128 | 0/46 |
| Age Continuous(years) | ABA 30/~10 mg/kg, Induction Period (IP) | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP | Total |
|---|---|---|---|---|---|
| Mean | 36.0 ± 11.12 | 38.6 ± 12.90 | 36.9 ± 13.35 | 38.0 ± 12.98 | 37.6 ± 12.81 |
| Age, Customized(Participants) | ABA 30/~10 mg/kg, Induction Period (IP) | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP | Total |
|---|---|---|---|---|---|
| <30 years | 23 | 37 | 51 | 41 | 152 |
| Between 30 and 50 years | 35 | 64 | 57 | 64 | 220 |
| >50 years | 7 | 27 | 22 | 23 | 79 |
| Sex: Female, Male(Participants) | ABA 30/~10 mg/kg, Induction Period (IP) | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP | Total |
|---|---|---|---|---|---|
| Female | 38 | 78 | 78 | 83 | 277 |
| Male | 27 | 50 | 52 | 45 | 174 |
| Region of Enrollment(participants) | ABA 30/~10 mg/kg, Induction Period (IP) | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP | Total |
|---|---|---|---|---|---|
| United States | 24 | 45 | 46 | 38 | 153 |
| Italy | 0 | 5 | 5 | 5 | 15 |
| Switzerland | 2 | 4 | 3 | 1 | 10 |
| India | 1 | 3 | 2 | 2 | 8 |
| France | 6 | 8 | 7 | 7 | 28 |
| Czech Republic | 1 | 2 | 0 | 2 | 5 |
| Mexico | 1 | 4 | 0 | 3 | 8 |
| Puerto Rico | 1 | 0 | 0 | 2 | 3 |
| Canada | 8 | 18 | 22 | 27 | 75 |
| Brazil | 3 | 7 | 6 | 6 | 22 |
| Belgium | 2 | 7 | 9 | 13 | 31 |
| Korea, Democratic People's Republic of | 1 | 1 | 1 | 1 | 4 |
| Denmark | 1 | 4 | 10 | 2 | 17 |
| Australia | 6 | 10 | 13 | 13 | 42 |
| South Africa | 5 | 5 | 1 | 2 | 13 |
| Germany | 0 | 2 | 2 | 3 | 7 |
| Netherlands | 3 | 3 | 3 | 1 | 10 |
| Inadequate Response/Intolerance to Prior Anti-Tumor Necrosis Factor (TNF) Agent Therapy(Participants) | ABA 30/~10 mg/kg, Induction Period (IP) | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP | Total |
|---|---|---|---|---|---|
| Inadequate Response/Intolerance To Prior Agents | 42 | 86 | 77 | 77 | 282 |
| No Inadequate Response/Intolerance To Prior Agents | 23 | 42 | 53 | 51 | 169 |
| Crohn's Disease (CD) Duration(Years) | ABA 30/~10 mg/kg, Induction Period (IP) | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP | Total |
|---|---|---|---|---|---|
| Mean | 8.4 ± 7.49 | 9.9 ± 8.74 | 9.2 ± 7.98 | 9.8 ± 8.29 | 9.5 ± 8.21 |
| Crohn's Disease Activity Index (CDAI)(points) | ABA 30/~10 mg/kg, Induction Period (IP) | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP | Total |
|---|---|---|---|---|---|
| Mean | 320.6 ± 61.59 | 318.9 ± 65.08 | 317.9 ± 59.87 | 320.7 ± 72.09 | 319.4 ± 65.03 |
| Inflammatory Bowel Disease Questionnaire (IBDQ) Score(units on a scale) | ABA 30/~10 mg/kg, Induction Period (IP) | ABA ~10 mg/kg, IP | ABA 3 mg/kg, IP | Placebo, IP | Total |
|---|---|---|---|---|---|
| Mean | 119.9 ± 26.22 | 117.3 ± 30.60 | 121.1 ± 28.0 | 119.6 ± 31.17 | 119.5 ± 29.36 |
Showing the first 100 of 101 sites across 17 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2006, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept